Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
15.7M
Short interest
settlement 2026-10-15
13.4
Days to cover
+3.2 days vs prior
53.5%
Short share of volume
2026-11-02
400
Fails to deliver
settlement 2026-10-07
Tue 10 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in OLMA is 15,678,877 shares, down 389,592 shares over the last month. Over the last 48 readings it ranged from 5,434,318 shares (30 April 2025) to 16,068,469 shares (15 September 2026). The latest reading sits at the top of that range. At the reported average volume of 1.2M shares a day that is 13.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/olma" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 15,678,877 | +6.7% | 1,172,110 | 13.38 |
| 2026-09-30 | 14,696,219 | -8.5% | 1,441,960 | 10.19 |
| 2026-09-15 | 16,068,469 | +2.6% | 1,008,452 | 15.93 |
| 2026-08-31 | 15,663,548 | -0.9% | 845,052 | 18.54 |
| 2026-08-14 | 15,808,921 | -1.0% | 1,109,534 | 14.25 |
| 2026-07-31 | 15,963,215 | +5.7% | 876,854 | 18.21 |
| 2026-07-15 | 15,101,848 | +7.6% | 1,337,327 | 11.29 |
| 2026-06-30 | 14,033,964 | +9.3% | 2,471,405 | 5.68 |
| 2026-06-15 | 12,843,113 | +7.7% | 1,630,801 | 7.88 |
| 2026-05-29 | 11,927,602 | +2.9% | 1,133,218 | 10.53 |
| 2026-05-15 | 11,587,581 | -11.2% | 1,131,257 | 10.24 |
| 2026-04-30 | 13,041,205 | +0.8% | 791,274 | 16.48 |
| 2026-04-15 | 12,934,118 | +5.5% | 887,866 | 14.57 |
| 2026-03-31 | 12,265,390 | +48.8% | 1,946,705 | 6.30 |
| 2026-03-13 | 8,240,774 | -0.2% | 2,787,437 | 2.96 |
| 2026-02-27 | 8,257,215 | -8.3% | 1,103,396 | 7.48 |
| 2026-02-13 | 9,002,172 | -11.0% | 1,577,543 | 5.71 |
| 2026-01-30 | 10,111,842 | +11.1% | 919,949 | 10.99 |
| 2026-01-15 | 9,100,561 | -12.5% | 1,450,644 | 6.27 |
| 2025-12-31 | 10,399,087 | -6.2% | 2,002,876 | 5.19 |
| 2025-12-15 | 11,090,858 | +2.6% | 3,187,370 | 3.48 |
| 2025-11-28 | 10,810,748 | +15.4% | 14,336,833 | 1.00 |
| 2025-11-14 | 9,364,250 | +11.9% | 941,184 | 9.95 |
| 2025-10-31 | 8,366,665 | +10.9% | 1,626,583 | 5.14 |
| 2025-10-15 | 7,545,885 | -3.1% | 1,196,980 | 6.30 |
| 2025-09-30 | 7,791,509 | -5.4% | 1,132,554 | 6.88 |
| 2025-09-15 | 8,239,433 | -2.1% | 1,752,554 | 4.70 |
| 2025-08-29 | 8,413,141 | -0.8% | 318,468 | 26.42 |
| 2025-08-15 | 8,481,885 | +11.1% | 587,221 | 14.44 |
| 2025-07-31 | 7,636,164 | -0.0% | 433,334 | 17.62 |
| 2025-07-15 | 7,638,452 | -6.2% | 419,029 | 18.23 |
| 2025-06-30 | 8,146,227 | +21.6% | 1,160,076 | 7.02 |
| 2025-06-13 | 6,700,924 | +6.4% | 1,045,055 | 6.41 |
| 2025-05-30 | 6,299,540 | +6.7% | 508,638 | 12.39 |
| 2025-05-15 | 5,903,528 | +8.6% | 840,566 | 7.02 |
| 2025-04-30 | 5,434,318 | -10.7% | 773,591 | 7.02 |
| 2025-04-15 | 6,082,523 | -6.5% | 1,233,351 | 4.93 |
| 2025-03-31 | 6,503,169 | -25.1% | 1,104,579 | 5.89 |
| 2025-03-14 | 8,685,944 | +2.6% | 773,311 | 11.23 |
| 2025-02-28 | 8,466,634 | +3.0% | 749,458 | 11.30 |
| 2025-02-14 | 8,215,916 | -2.3% | 899,500 | 9.13 |
| 2025-01-31 | 8,412,251 | -22.6% | 1,259,669 | 6.68 |
| 2025-01-15 | 10,873,224 | +4.5% | 1,381,170 | 7.87 |
| 2024-12-31 | 10,399,932 | +4.4% | 1,193,872 | 8.71 |
| 2024-12-13 | 9,965,564 | -0.5% | 1,280,655 | 7.78 |
| 2024-11-29 | 10,015,332 | +17.0% | 678,960 | 14.75 |
| 2024-11-15 | 8,562,407 | +3.0% | 482,768 | 17.74 |
| 2024-10-31 | 8,309,802 | -2.2% | 315,596 | 26.33 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of OLMA volume is 53.5%, up 33.0 points over the last five sessions. Over the last 30 readings it ranged from 20.6% (26 October 2026) to 80.4% (2 October 2026). The latest reading is 5.8 points below the 30-session average of 59.3%, on 344K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 184K | 344K | 53.5% | 0 |
| 2026-10-30 | 138K | 228K | 60.7% | 240 |
| 2026-10-29 | 314K | 442K | 71.0% | 16 |
| 2026-10-28 | 460K | 617K | 74.7% | 940 |
| 2026-10-27 | 544K | 869K | 62.6% | 0 |
| 2026-10-26 | 186K | 906K | 20.6% | 10,765 |
| 2026-10-23 | 353K | 810K | 43.5% | 1,059 |
| 2026-10-22 | 208K | 520K | 40.1% | 0 |
| 2026-10-21 | 317K | 565K | 56.1% | 0 |
| 2026-10-20 | 660K | 1.1M | 61.5% | 0 |
| 2026-10-19 | 272K | 504K | 54.1% | 0 |
| 2026-10-16 | 236K | 452K | 52.3% | 0 |
| 2026-10-15 | 248K | 381K | 65.0% | 0 |
| 2026-10-14 | 443K | 707K | 62.6% | 254 |
| 2026-10-13 | 370K | 551K | 67.2% | 125 |
| 2026-10-12 | 341K | 450K | 75.7% | 0 |
| 2026-10-09 | 191K | 284K | 67.4% | 0 |
| 2026-10-08 | 200K | 364K | 55.1% | 6,289 |
| 2026-10-07 | 253K | 380K | 66.5% | 0 |
| 2026-10-06 | 280K | 512K | 54.7% | 0 |
| 2026-10-05 | 266K | 393K | 67.8% | 633 |
| 2026-10-02 | 390K | 485K | 80.4% | 0 |
| 2026-10-01 | 230K | 408K | 56.4% | 0 |
| 2026-09-30 | 420K | 626K | 67.0% | 0 |
| 2026-09-29 | 290K | 446K | 65.1% | 0 |
| 2026-09-28 | 258K | 444K | 58.1% | 0 |
| 2026-09-25 | 363K | 556K | 65.2% | 0 |
| 2026-09-24 | 319K | 662K | 48.2% | 13 |
| 2026-09-23 | 465K | 827K | 56.2% | 0 |
| 2026-09-22 | 366K | 729K | 50.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 7 October 2026, the fails-to-deliver balance in OLMA is 400 shares, up 189 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (13 July 2026) to 22,049 shares (2 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-07 | 400 | $7.92 | $3K |
| 2026-09-15 | 211 | $10.29 | $2K |
| 2026-09-11 | 100 | $10.69 | $1K |
| 2026-09-10 | 2 | $10.36 | $21 |
| 2026-08-27 | 2,913 | $10.85 | $32K |
| 2026-08-21 | 20 | $10.90 | $218 |
| 2026-08-05 | 81 | $11.76 | $953 |
| 2026-08-03 | 135 | $11.45 | $2K |
| 2026-07-28 | 79 | $12.01 | $949 |
| 2026-07-22 | 777 | $11.59 | $9K |
| 2026-07-20 | 5,000 | $11.47 | $57K |
| 2026-07-15 | 50 | $11.85 | $593 |
| 2026-07-13 | 1 | $11.91 | $12 |
| 2026-07-06 | 7,015 | $12.64 | $89K |
| 2026-07-02 | 22,049 | $12.08 | $266K |
| 2026-06-30 | 2 | $12.20 | $24 |
| 2026-06-29 | 363 | $11.39 | $4K |
| 2026-06-26 | 33 | $11.43 | $377 |
| 2026-05-22 | 2,790 | $14.06 | $39K |
| 2026-05-18 | 7,229 | $13.59 | $98K |
| 2026-05-13 | 62 | $13.97 | $866 |
| 2026-05-08 | 4,009 | $15.13 | $61K |
| 2026-05-07 | 2,358 | $15.19 | $36K |
| 2026-05-06 | 140 | $14.64 | $2K |
| 2026-05-05 | 3,620 | $14.63 | $53K |
| 2026-05-04 | 8,445 | $14.32 | $121K |
| 2026-04-28 | 326 | $15.29 | $5K |
| 2026-04-21 | 2,178 | $16.58 | $36K |
| 2026-04-20 | 5,870 | $16.82 | $99K |
| 2026-04-17 | 5,525 | $16.48 | $91K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for OLMA in the last 90 days. The most recent filings are listed below. Latest filing: Harmon Cyrus (Director) on 2026-07-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-24 | Harmon Cyrus | Director | Sell | 13K | $11.71 | $146K | 703K |
| 2026-07-23 | Harmon Cyrus | Director | Sell | 13K | $11.58 | $145K | 715K |
| 2026-03-04 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Sell | 233 | $24.69 | $6K | 0 |
| 2026-03-04 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Sell | 25K | $24.25 | $601K | 233 |
| 2026-03-04 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Exercise or conversion | 25K | $4.37 | $109K | 25K |
| 2026-03-03 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Sell | 15K | $23.01 | $345K | 0 |
| 2026-03-03 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Exercise or conversion | 15K | $4.37 | $66K | 15K |
| 2026-02-02 | Austin Sasha Lu | VP of Finance and Controller | Grant | 12K | $0.00 | $0 | 16K |
| 2026-01-20 | Harmon Cyrus | Director | Sell | 10K | $26.88 | $269K | 728K |
| 2026-01-15 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 100K | $28.73 | $2.9M | 140K |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 35K | $28.99 | $1.0M | 543K |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 15K | $28.60 | $429K | 578K |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Exercise or conversion | 50K | $4.87 | $244K | 593K |
| 2026-01-14 | Harmon Cyrus | Director | Sell | 3K | $29.12 | $102K | 738K |
| 2026-01-13 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 200 | $28.49 | $6K | 543K |
| 2026-01-13 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 50K | $27.60 | $1.4M | 543K |
| 2026-01-13 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Exercise or conversion | 50K | $4.87 | $244K | 593K |
| 2026-01-13 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 4K | $28.01 | $107K | 240K |
| 2026-01-12 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 10K | $28.34 | $283K | 145K |
| 2025-12-26 | Bohen Sean | President and CEO | Gift | 9K | $0.00 | $0 | 238K |
| 2025-12-23 | Zojwalla Naseem | Chief Medical Officer | Sell | 100K | $27.66 | $2.8M | 4K |
| 2025-12-23 | Zojwalla Naseem | Chief Medical Officer | Exercise or conversion | 50K | $7.02 | $351K | 104K |
| 2025-12-22 | Zojwalla Naseem | Chief Medical Officer | Sell | 100K | $28.04 | $2.8M | 54K |
| 2025-12-22 | Zojwalla Naseem | Chief Medical Officer | Exercise or conversion | 7K | $7.02 | $50K | 154K |
| 2025-12-22 | Zojwalla Naseem | Chief Medical Officer | Exercise or conversion | 43K | $15.25 | $653K | 147K |
| 2025-12-22 | Harmon Cyrus | Director | Sell | 3K | $28.53 | $82K | 741K |
| 2025-12-19 | CLARK IAN T | Director | Exercise or conversion | 22K | $7.84 | $169K | 253K |
| 2025-12-19 | Zojwalla Naseem | Chief Medical Officer | Sell | 13K | $28.93 | $374K | 104K |
| 2025-12-19 | Zojwalla Naseem | Chief Medical Officer | Sell | 57K | $28.03 | $1.6M | 117K |
| 2025-12-19 | Zojwalla Naseem | Chief Medical Officer | Exercise or conversion | 40K | $15.25 | $610K | 174K |
| 2025-12-19 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Gift | 9K | $0.00 | $0 | 543K |
| 2025-12-19 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 6K | $31.39 | $190K | 552K |
| 2025-12-19 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 44K | $30.40 | $1.3M | 558K |
| 2025-12-19 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 1K | $28.08 | $34K | 602K |
| 2025-12-19 | CLARK IAN T | Director | Sell | 42K | $30.48 | $1.3M | 0 |
| 2025-12-19 | CLARK IAN T | Director | Sell | 193K | $29.71 | $5.7M | 42K |
| 2025-12-19 | CLARK IAN T | Director | Sell | 30K | $28.83 | $862K | 235K |
| 2025-12-19 | CLARK IAN T | Director | Exercise or conversion | 12K | $4.08 | $49K | 265K |
| 2025-12-19 | CLARK IAN T | Director | Exercise or conversion | 22K | $3.61 | $78K | 231K |
| 2025-12-19 | CLARK IAN T | Director | Exercise or conversion | 210K | $4.41 | $924K | 210K |
| 2025-12-08 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Gift | 75K | $0.00 | $0 | 244K |
| 2025-11-26 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Gift | 225K | $0.00 | $0 | 319K |
| 2025-11-25 | RAPPAPORT ANDREW | Director | Gift | 36K | $0.00 | $0 | 0 |
| 2025-11-21 | RAPPAPORT ANDREW | Director | Exercise or conversion | 36K | $0.39 | $14K | 36K |
| 2025-09-18 | Harmon Cyrus | Director | Sell | 3K | $8.32 | $26K | 117K |
| 2025-09-18 | Harmon Cyrus | Director | Sell | 10K | $8.33 | $83K | 744K |
| 2025-09-16 | Harmon Cyrus | Director | Sell | 2K | $8.08 | $15K | 120K |
| 2025-09-16 | Harmon Cyrus | Director | Sell | 10K | $8.04 | $80K | 754K |
| 2025-01-10 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | Other transaction | 3.5M | price not stated in the filing | not stated | 4.3M |
| 2025-01-10 | BVF Partners OS Ltd. | Director,Other | Returned to company | 23K | price not stated in the filing | not stated | 348K |
| 2025-01-10 | BVF Partners OS Ltd. | Director,Other | Returned to company | 235K | price not stated in the filing | not stated | 2.7M |
| 2025-01-10 | BVF Partners OS Ltd. | Director,Other | Returned to company | 162K | price not stated in the filing | not stated | 2.0M |
| 2025-01-08 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | Buy | 300K | $5.76 | $1.7M | 7.8M |
| 2024-12-17 | Graham G. Walmsley | Director | Sell | 701K | $6.75 | $4.7M | 0 |
| 2024-12-17 | Graham G. Walmsley | Director | Buy | 701K | $6.75 | $4.7M | 1.4M |
| 2024-12-16 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Exercise or conversion | 14K | $4.87 | $68K | 130K |
| 2024-12-13 | Graham G. Walmsley | Director | Buy | 701K | $6.75 | $4.7M | 701K |
| 2024-12-13 | Graham G. Walmsley | Director | Sell | 701K | $6.75 | $4.7M | 0 |
| 2024-12-11 | Bohen Sean | PRESIDENT AND CEO | Sell | 56K | $8.66 | $484K | 243K |
| 2024-12-11 | Bohen Sean | PRESIDENT AND CEO | Sell | 1K | $9.39 | $12K | 242K |
| 2024-12-11 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 406 | $9.39 | $4K | 544K |
| 2024-12-11 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 18K | $8.66 | $155K | 544K |
| 2024-12-11 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Sell | 14K | $8.66 | $123K | 116K |
| 2024-12-11 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Sell | 320 | $9.39 | $3K | 116K |
| 2024-12-11 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 13K | $8.66 | $115K | 599K |
| 2024-12-11 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 300 | $9.39 | $3K | 598K |
| 2024-12-11 | Harmon Cyrus | Director | Sell | 179 | $9.39 | $2K | 764K |
| 2024-12-11 | Harmon Cyrus | Director | Sell | 8K | $8.66 | $69K | 764K |
| 2024-12-10 | Bohen Sean | PRESIDENT AND CEO | Sell | 52K | $9.37 | $490K | 299K |
| 2024-12-10 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 17K | $9.37 | $157K | 562K |
| 2024-12-10 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Sell | 13K | $9.37 | $124K | 130K |
| 2024-12-10 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 12K | $9.38 | $117K | 612K |
| 2024-12-10 | Harmon Cyrus | Director | Sell | 8K | $9.37 | $77K | 772K |
| 2024-12-09 | Bohen Sean | PRESIDENT AND CEO | Grant | 205K | $0.00 | $0 | 351K |
| 2024-12-09 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Grant | 68K | $0.00 | $0 | 579K |
| 2024-12-09 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Grant | 52K | $0.00 | $0 | 143K |
| 2024-12-09 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Grant | 49K | $0.00 | $0 | 624K |
| 2024-12-09 | Harmon Cyrus | Director | Grant | 29K | $0.00 | $0 | 781K |
| 2024-12-04 | BVF INC/IL | Director,Other | Returned to company | 153K | price not stated in the filing | not stated | 371K |
| 2024-12-04 | BVF INC/IL | Director,Other | Returned to company | 1.8M | price not stated in the filing | not stated | 2.9M |
| 2024-12-04 | BVF INC/IL | Director,Other | Returned to company | 1.4M | price not stated in the filing | not stated | 2.2M |
| 2024-11-15 | Kovacs Shane William Charles | Ch. Operating & Financial Off. | Exercise or conversion | 25K | $7.02 | $176K | 510K |
| 2024-08-01 | Paradigm Biocapital Advisors LP | TenPercentOwner | Sell | 1.9M | $14.92 | $27.9M | 4.7M |
| 2024-08-01 | Paradigm Biocapital Advisors LP | TenPercentOwner | Sell | 530K | $14.92 | $7.9M | 783K |
| 2024-07-30 | Harmon Cyrus | Director | Sell | 934 | $15.55 | $15K | 751K |
| 2024-07-29 | Harmon Cyrus | Director | Sell | 4K | $15.58 | $63K | 752K |
| 2024-07-11 | Harmon Cyrus | Director | Sell | 5K | $12.26 | $61K | 756K |
| 2024-06-28 | Harmon Cyrus | Director | Sell | 20K | $10.77 | $215K | 761K |
| 2024-06-04 | Harmon Cyrus | Director | Sell | 5K | $12.33 | $62K | 781K |
| 2024-06-04 | Graham G. Walmsley | Director | Sell | 700K | $14.85 | $10.4M | 701K |
| 2024-06-04 | Graham G. Walmsley | Director | Sell | 475K | $14.85 | $7.1M | 708K |
| 2024-06-03 | Harmon Cyrus | Director | Sell | 5K | $10.93 | $55K | 786K |
| 2024-05-31 | Harmon Cyrus | Director | Sell | 15K | $9.41 | $141K | 791K |
| 2024-05-24 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Exercise or conversion | 9K | $4.87 | $46K | 90K |
| 2024-05-06 | Harmon Cyrus | Director | Sell | 5K | $10.92 | $55K | 806K |
| 2024-04-30 | Harmon Cyrus | Director | Sell | 15K | $9.51 | $143K | 811K |
| 2024-03-28 | Harmon Cyrus | Director | Sell | 20K | $10.97 | $219K | 826K |
| 2024-03-18 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Exercise or conversion | 14K | $4.87 | $67K | 80K |
| 2024-03-05 | RAPPAPORT ANDREW | Director | Other transaction | 481K | $0.00 | $0 | 0 |
| 2024-03-05 | RAPPAPORT ANDREW | Director | Other transaction | 386K | $0.00 | $0 | 386K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON30 Form 144 notices on file for OLMA worth $33.7M at the prices reported; 0 in the last 90 days worth $0. Latest: Harmon Cyrus filed on 2026-07-24 to sell 12,500 shares ($146K) from 2026-07-24.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-24 | Harmon CyrusDirector | 13K | $146K | 0.014% | 2026-07-24 | Fidelity Brokerage Services LLC |
| 2026-07-23 | Harmon CyrusDirector | 13K | $145K | 0.014% | 2026-07-23 | Fidelity Brokerage Services LLC |
| 2026-03-16 | Kovacs Shane William CharlesFormer Officer | 4K | $69K | 0.005% | 2026-03-16 | Fidelity Brokerage Services LLC |
| 2026-03-16 | Kovacs Shane William CharlesFormer Officer | 100K | $1.6M | 0.115% | 2026-03-16 | Fidelity Brokerage Services LLC |
| 2026-03-11 | Kovacs Shane William CharlesFormer Officer | 50K | $797K | 0.073% | 2026-03-11 | Fidelity Brokerage Services LLC |
| 2026-03-10 | Kovacs Shane William CharlesFormer Officer | 53K | $905K | 0.077% | 2026-03-10 | Fidelity Brokerage Services LLC |
| 2026-03-09 | Kovacs Shane William CharlesFormer Officer | 242K | $3.3M | 0.352% | 2026-03-09 | Fidelity Brokerage Services LLC |
| 2026-03-04 | Mitchell ShawnteOfficer | 25K | $599K | 0.036% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2026-03-04 | Kovacs Shane William CharlesFormer Officer | 20K | $489K | 0.029% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Mitchell ShawnteOfficer | 15K | $345K | 0.022% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-02-27 | Kovacs Shane William CharlesFormer Officer | 7K | $163K | 0.009% | 2026-02-27 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Kovacs Shane William CharlesFormer Officer | 20K | $500K | 0.029% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Kovacs Shane William CharlesFormer Officer | 10K | $243K | 0.015% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Kovacs Shane William CharlesFormer Officer | 20K | $480K | 0.029% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-12 | Kovacs Shane William CharlesFormer Officer | 10K | $238K | 0.015% | 2026-02-12 | Fidelity Brokerage Services LLC |
| 2026-01-20 | Harmon CyrusDirector | 10K | $269K | 0.015% | 2026-01-20 | Fidelity Brokerage Services LLC |
| 2026-01-15 | Kovacs Shane William CharlesOfficer | 100K | $2.9M | 0.146% | 2026-01-15 | Fidelity Brokerage Services LLC |
| 2026-01-14 | Myles David C.Officer | 50K | $1.4M | 0.073% | 2026-01-14 | Fidelity Brokerage Services LLC |
| 2026-01-14 | Harmon CyrusDirector | 3K | $102K | 0.005% | 2026-01-14 | Fidelity Brokerage Services LLC |
| 2026-01-13 | Myles David C.Officer | 50K | $1.4M | 0.073% | 2026-01-13 | Fidelity Brokerage Services LLC |
| 2026-01-13 | Kovacs Shane William CharlesOfficer | 4K | $107K | 0.006% | 2026-01-13 | Fidelity Brokerage Services LLC |
| 2026-01-12 | Myles David C.Officer | 10K | $283K | 0.015% | 2026-01-12 | Fidelity Brokerage Services LLC |
| 2025-12-23 | Zojwalla NaseemOfficer | 100K | $2.8M | 0.145% | 2025-12-23 | Fidelity Brokerage Services LLC |
| 2025-12-22 | Zojwalla NaseemOfficer | 100K | $2.8M | 0.146% | 2025-12-22 | Fidelity Brokerage Services LLC |
| 2025-12-22 | Harmon CyrusOfficer | 3K | $82K | 0.004% | 2025-12-22 | Fidelity Brokerage Services LLC |
| 2025-12-19 | Zojwalla NaseemOfficer | 70K | $2.0M | 0.102% | 2025-12-19 | Fidelity Brokerage Services LLC |
| 2025-12-19 | Myles David C.Officer | 51K | $1.6M | 0.074% | 2025-12-19 | Fidelity Brokerage Services LLC |
| 2025-12-19 | CLARK IAN TDirector | 265K | $7.9M | 0.386% | 2025-12-19 | Fidelity Brokerage Services LLC |
| 2025-09-18 | Harmon CyrusDirector | 13K | $109K | 0.019% | 2025-09-18 | Fidelity Brokerage Services LLC |
| 2025-09-16 | Harmon CyrusDirector | 12K | $96K | 0.017% | 2025-09-16 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of OLMA in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is FMR LLC at 13.8% of the class (12,075,062 shares), filed 2026-08-06 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-16 | 13D/Ano. 4 | LAMPERT MARK Nindividual | 8.9M | 9.8% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BVF INC/ILcorporation | 8.9M | 9.8% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BVF PARTNERS L P/ILinvestment adviser, partnership | 8.9M | 9.8% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BVF GP HOLDINGS LLCother entity | 8.3M | 9.1% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 5.9M | 6.6% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BVF I GP LLCother entity | 5.9M | 6.6% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 2.4M | 2.7% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BVF II GP LLCother entity | 2.4M | 2.7% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | Biotechnology Value Trading Fund OS LPpartnership | 348K | 0.4% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | BVF Partners OS Ltd.corporation | 348K | 0.4% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 4 | Hrustanovic Gorjanindividual | 184K | 0.2% | 2026-10-14 |
| 2026-08-06 | 13G/Ano. 2 | FMR LLCparent holding company | 12.1M | 13.8% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 2 | Abigail P. Johnsonindividual | 12.1M | 13.8% | 2026-06-30 |
| 2026-07-29 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 6.2M | 7.1% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 2 | JANUS HENDERSON GROUP PLCparent holding company | 7.1M | 8.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Bain Capital Life Sciences Opportunities IV, L.P.partnership | 7.5M | 8.2% | 2026-03-31 |
| 2026-03-20 | 13G | Raymond Debbaneindividual | 4.5M | 5.1% | 2026-03-16 |
| 2026-03-20 | 13G | Invus Public Equities, L.P.partnership | 3.9M | 4.5% | 2026-03-16 |
| 2026-03-20 | 13G | Invus Public Equities Advisors, LLCother entity | 3.9M | 4.5% | 2026-03-16 |
| 2026-03-20 | 13G | Invus Global Management, LLCother entity | 3.9M | 4.5% | 2026-03-16 |
| 2026-03-20 | 13G | Siren, L.L.C.other entity | 3.9M | 4.5% | 2026-03-16 |
| 2026-03-20 | 13G | Avicenna Life Sci Master GP LLCother entity | 563K | 0.6% | 2026-03-16 |
| 2026-03-20 | 13G | Ulys, L.L.C.other entity | 563K | 0.6% | 2026-03-16 |
| 2026-03-20 | 13G | Avicenna Life Sci Master Fund LPpartnership | 563K | 0.6% | 2026-03-16 |
| 2026-02-13 | 13G/Ano. 3 | Deep Track Capital, LPinvestment adviser, other entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 3 | Deep Track Biotechnology Master Fund, Ltd.corporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 3 | David Kroinparent holding company, individual | 0 | 0.0% | 2025-12-31 |
13F holders
Tracked managers holding OLMA at their latest 13F. JSON7 of the 30 tracked managers held OLMA at their latest 13F, $53.3M in total at quarter-end prices. Two Sigma Investments is the largest at $14.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.1M | $14.2M | 0.01% | -38K |
| Point72 Asset Management | 2026-06-30 | 1.1M | $13.4M | 0.01% | +1000K |
| Duquesne Family Office | 2026-06-30 | 987K | $12.3M | 0.24% | 0 |
| Citadel Advisors | 2026-06-30 | 642K | $8.0M | 0.00% | -264K |
| Fisher Asset Management | 2026-06-30 | 297K | $3.7M | 0.00% | -3K |
| AQR Capital Management | 2026-06-30 | 78K | $978K | 0.00% | -11K |
| D. E. Shaw & Co. | 2026-06-30 | 56K | $695K | 0.00% | +16K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Olema Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Olema Pharmaceuticals (OLMA), SEC CIK 1750284, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-07.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-24.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-16.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1750284Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of OLMA is sold short?
15,678,877 shares were held short at the 2026-10-15 settlement, 13.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is OLMA's daily short volume?
On 2026-11-02, 184,256 of the 344,259 OLMA shares reported to FINRA were sold short, 53.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does OLMA have fails to deliver?
The SEC's latest file shows 400 OLMA shares failed to deliver at settlement 2026-10-07. Fails are reported per settlement date and published twice a month with a lag.
Are OLMA insiders buying or selling?
No open-market insider trades were reported for OLMA in the last 90 days. The most recent filings are listed below. Latest filing: Harmon Cyrus (Director) on 2026-07-24.
Have OLMA insiders filed to sell?
30 Form 144 notices on file for OLMA worth $33.7M at the prices reported; 0 in the last 90 days worth $0. Latest: Harmon Cyrus filed on 2026-07-24 to sell 12,500 shares ($146K) from 2026-07-24.
Who owns 5% or more of OLMA?
12 holders report 5% or more of OLMA in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is FMR LLC at 13.8% of the class (12,075,062 shares), filed 2026-08-06 for an event on 2026-06-30.
Which tracked 13F managers own OLMA?
7 of the 30 tracked 13F managers held OLMA shares at their latest filing, $53.3M in all. The largest: Two Sigma Investments (1.1M shares, $14.2M), Steve Cohen's Point72 Asset Management (1.1M shares, $13.4M), Stanley Druckenmiller's Duquesne Family Office (987K shares, $12.3M), Ken Griffin's Citadel Advisors (642K shares, $8.0M), Ken Fisher's Fisher Asset Management (297K shares, $3.7M), Cliff Asness's AQR Capital Management (78K shares, $978K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.